August 21, 2023 — How much might the application of new insights from the SELECT study of treating obesity do for preventing heart attacks, strokes, and deaths. A first pass at answering this question appeared in Cardiovascular Drugs and Therapy last week. Nathan Wong, Hridhay Karthikeyan, and Wenjun Fan estimated the potential for semaglutide treatment to lower cardiovascular disease […]
September 17, 2022 — Yesterday, the Institute for Clinical and Economic Review conducted an impressive public hearing on the effectiveness and value of obesity medicines. ICER deserves credit for developing a complex and remarkably transparent model for objectively evaluating this. However, caution is necessary. This model is sufficiently complex to obscure two important facts about obesity and its treatment. […]
September 3, 2022 — ICER – the Institute for Clinical and Economic Review – has released its final report on the effectiveness and value of obesity meds and set a public hearing for September 16. Let’s say it right up front. This private nonprofit is trying to do something that is almost impossibly hard. Making objective sense from the […]
July 14, 2022 — We’ve all got our reading assignments. The Institute for Clinical and Economic Review (ICER) has released its draft report on effectiveness and value for the current options in obesity medicine. There’s a lot to process in there. But the bottom line is clear enough. Phentermine/topiramate (Qsymia) offers the best value, says the report. The most […]
